4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-22-043961
Chief Scientific Officer sold 1,186 shares at $15.67 ($18,585)
- Chief Scientific Officer acquired 3,207 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hansen Gwenn Chief Scientific Officer | 2022-07-30 | Option exercise | +3,207 | 20,358 | D: show line 1 in the form | ||
| Hansen Gwenn Chief Scientific Officer | 2022-08-01 | Sale | −1,186 | $15.67 | $18,585 | 19,172 | D: show line 2 in the form |
| Open-market sales · 1,186 sh · avg $15.67 · $18,585 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Hansen Gwenn Chief Scientific Officer | 2022-07-30 | Option exercise · Restricted Stock Units | −3,207 | 44,895 | D: show line 3 in the form |
Loading xslF345X03/doc4.xml…